Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer von Baka, S., Manegold, C., Buchholz, E., Schott-von-Römer, K., Lorigan, P., Nagel, S., Blackhall, F., Aschroft, L., Thatcher, N.

Volltext

Clinical prognostic factors in advanced non-small cell lung cancer (NSCLC): Cox regression analysis based on 789 patients treated in three consecutive randomized trials von Pilz, L. R., Thatcher, N., Kortsik, C., Koschel, G., Mezger, J., Schott von Römer, K., Manegold, C.

Volltext

Biomarker analysis from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC) von Schneider, C., Schott-von Römer, K., Gütz, S., Raack, B., Dierkesmann, R., Laack, E., Guschall, W., Schmittel, A., Gatzemeier, U.

Volltext

Sequencing of single-agent (SA) docetaxel (T) and gemcitabine (G) therapy for patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of three consecutive randomiz... von Manegold, C., Thatcher, N., Kortsik, C., Koschel, G., Mezger, J., Schott Von Römer, K., Pilz, L. R.

Volltext